ICMR AMR annual report (2023-24) Summary

Key Themes and Findings:

Dominant Organisms and Specimen Distribution:

    • Enterobacterales: The most frequently isolated group of organisms across all specimens. They make up a significant proportion of isolates, particularly in blood, urine, and lower respiratory tract (LRT) samples. Specifically, Enterobacterales, excluding Salmonella and Shigella, accounted for 46.3% of all positive cultures. Escherichia coli and Klebsiella pneumoniae are frequently observed Enterobacterales.
    • Non-Fermenting Gram-Negative Bacilli (NFGNB): A significant proportion of isolates, especially in LRT samples. Acinetobacter baumannii and Pseudomonas aeruginosa are the predominant NFGNB. NFGNB accounted for 25% of all positive cultures.
    • Staphylococcus aureus and Coagulase-Negative Staphylococci (CoNS): Common, particularly in blood and superficial infections. Staphylococcus haemolyticus and Staphylococcus epidermidis are also found in significant numbers.
    • Enterococci: Significant presence in urine and deep infections, with Enterococcus faecalis being the most common species.
    • Fungi: Candida species are frequently isolated, predominantly from blood samples. Candida tropicalis and Candida albicans are most common, with the concerning presence of Candida auris. Fungal isolates made up 2.81% of isolates.
    • Diarrheal Pathogens: Predominantly isolated from faecal specimens.
    • Specific Specimen Observations:
    • Blood: Staphylococcus hominis, Salmonella Typhi, Staphylococcus spp. are the top isolates.
    • LRT: Stenotrophomonas maltophilia, Klebsiella spp., Proteus mirabilis and Serratia marcescens are frequent.
    • Superficial Infection: Proteus mirabilis and Morganella morganii are notable.
    • Deep Infection: Proteus mirabilis and Enterococcus spp. are common.
    • Faeces: A diverse range of organisms including Salmonella spp., Aeromonas spp., diarrheagenic E. coli, Vibrio cholerae, and Shigella species.

    Antimicrobial Resistance Trends:

      • Enterobacterales:
        • Significant resistance to commonly used antibiotics such as ciprofloxacin.
        • Carbapenem resistance is observed, with imipenem and meropenem showing reduced susceptibility.
        • E. coli and K. pneumoniae demonstrate varying levels of resistance to multiple antibiotic classes across different centres.
        • Fosfomycin shows relatively good susceptibility rates for Enterobacterales.
      • Salmonella Typhi:
        • High susceptibility to ampicillin, azithromycin, cefixime, ceftriaxone, and chloramphenicol.
        • Alarmingly high resistance to ciprofloxacin with some reduction in susceptibility to levofloxacin.
      • Shigella flexneri:
        • Significant resistance to ampicillin, with moderate resistance to trimethoprim-sulfamethoxazole
      • Stenotrophomonas maltophilia:
        • Generally susceptible to minocycline and trimethoprim-sulfamethoxazole.
      • Pseudomonas aeruginosa: Demonstrates carbapenem resistance with presence of metallo beta-lactamase genes such as NDM and VIM
      • Burkholderia cepacia: High rates of carbapenem resistance are seen with the presence of OXA23 & NDM resistance determinants.
      • Staphylococcus aureus:
        • High methicillin resistance (MRSA) rates, with variations across different regions.
        • Good susceptibility to vancomycin and teicoplanin.
        • Resistance to ciprofloxacin is high.
      • Enterococci:
        • High rates of resistance to vancomycin with the presence of the vanA gene.
      • Candida species:
        • Generally susceptible to anidulafungin, caspofungin, micafungin, voriconazole.
        • Candida auris has shown a significant resistance to fluconazole.
        • Candida glabrata has also shown resistance to fluconazole.

      Molecular Mechanisms of Resistance:

        • E. coli and K. pneumoniae: Resistance is often associated with specific genes:
          • blaNDM, blaOXA-48, blaCTX-M-15, blaTEM, blaSHV are prevalent.
          • The distribution of these genes varies significantly across different regional centres.
        • Salmonella spp.:
          • Resistance to fluoroquinolones is associated with mutations in gyrA and parC genes.
        • Pseudomonas aeruginosa: Carbapenem resistance is driven by metallo beta-lactamase such as blaNDM and blaVIM
        • Burkholderia cepacia: Resistance is driven by blaOXA23 and blaNDM genes.
        • Staphylococcus aureus:
          • hVISA (heteroresistant vancomycin-intermediate S. aureus) is associated with amino acid substitutions in graS, mprF and vraR genes.
          • Mupirocin resistance was found to be due to mupA genes.

        Trends Over Time:

          • Enterococcus species: Show a fluctuation in yearly isolation trends.
            • Year-2022 (%) 6965/ 107053 (6.5)
            • Year-2023 (%) 6999/ 99492 (7)
          • Candida species Show a fluctuation in yearly isolation trends.
            • Year-2020 (%) 2403/ 108465 (2.2)
            • Year-2023 (%) 2493/ 99492 (2.5)
          • Salmonella Typhi: Ceftriaxone MIC shows a fluctuating trend over the years. Azithromycin MIC also shows variability over the years.
            • The MIC50 and MIC90 for azithromycin in S. Typhi have varied over time.
          • Aeromonas spp.: Fluctuating rates of resistance to cefixime.
          • Shigella flexneri: Fluctuating rates of susceptibility to ampicillin and trimethoprim-sulfamethoxazole.

          Regional Variations:

          * The data reveals notable differences in the prevalence of specific organisms and resistance patterns across different surveillance centres, indicating the need for region-specific interventions.

          Implications:

          • The high prevalence of resistant organisms highlights the urgent need for antibiotic stewardship programs and infection prevention control measures.
          • The data on molecular mechanisms of resistance can inform the development of new diagnostic tools and therapeutic strategies.
          • The regional variations emphasize the importance of tailoring public health interventions to the local context.

          Recommendations:

          • Strengthen surveillance efforts to monitor the changing trends in AMR.
          • Implement robust antibiotic stewardship programs in hospitals and communities.
          • Promote research and development of new antibiotics and alternative therapies.
          • Enhance infection prevention and control practices to reduce the spread of resistant organisms.
          • Educate healthcare providers and the public about the rational use of antibiotics.

          Conclusion:

          The ICMR’s 2023 AMR Surveillance Network data highlights a complex and concerning scenario of antibiotic resistance in India. The findings underscore the need for a concerted, multi-pronged approach to tackle this global health threat. Continued surveillance, informed by molecular analysis, will be crucial for guiding effective strategies to mitigate the impact of AMR.

          Leave a Reply

          Your email address will not be published. Required fields are marked *